Stock Collapse Sparks Securities Investigation at Fulgent Genetics
Fulgent Genetics Inc. ($FLGT) faces a potential securities lawsuit following a dramatic 38.1% stock price collapse that wiped out significant shareholder value in a single trading session. On February 27, 2026, the genomics testing company announced sharply reduced full-year guidance, revealing that its largest customer had decided to move work in-house—a development that sent shares plummeting from $24.76 to $15.33 per share. The precipitous decline has prompted legal action, with the law firm Kirby McInerney LLP launching an investigation into potential violations of federal securities laws and now actively soliciting investors who purchased FLGT securities to participate in the probe.
The magnitude of the stock decline signals serious concerns among market participants about both the immediate financial impact and what the guidance revision may reveal about Fulgent Genetics' business model, customer concentration risk, and prior disclosures to investors. The loss of the company's largest customer represents not merely a single account disruption but a fundamental threat to revenue streams and profitability projections that the company had presumably communicated to shareholders.
The February 27 Earnings Surprise and Its Implications
The February 27 announcement appears to have caught investors by surprise, suggesting that Fulgent Genetics either failed to adequately warn shareholders about escalating customer concentration risks or failed to disclose information about discussions with its largest customer regarding potential in-house operations. Key factors underlying the investigation include:
- Customer concentration vulnerability: The company's reliance on a single major customer for substantial revenue became catastrophically apparent, raising questions about risk disclosures
- Timing of disclosure: The announcement came without apparent prior warning to investors, suggesting either a sudden development or inadequate disclosure practices
- Magnitude of impact: A 38.1% single-day decline typically suggests material information was previously undisclosed or misrepresented
- Guidance revision scope: The significantly reduced 2026 guidance indicates the customer relationship loss will materially impact full-year performance
Investors now face the critical question of whether Fulgent Genetics management knew about the customer's intentions to move operations in-house before issuing prior guidance and investor communications. Securities law requires public companies to disclose material risks and developments in a timely manner. If management possessed knowledge of customer defection discussions yet continued making optimistic revenue projections, this could constitute securities fraud.
Market Context and Industry Pressures
The Fulgent Genetics situation reflects broader challenges in the genomics and genetic testing sector, where consolidation, pricing pressure, and vertical integration pose ongoing threats to independent testing companies. Several contextual factors help explain this crisis:
Sector Consolidation and Vertical Integration: Large healthcare systems and pharmaceutical companies increasingly develop in-house genetic testing capabilities rather than outsourcing to specialized providers. This trend threatens the business model of companies like Fulgent Genetics that depend on outsourced testing volume.
Customer Concentration Risk: The fact that Fulgent Genetics apparently depends heavily on a single customer suggests the company has not achieved sufficient diversification of its revenue base—a red flag that should have been more prominently disclosed to investors.
Pricing and Reimbursement Pressures: The genetic testing industry faces ongoing pressure from managed care providers on reimbursement rates, potentially motivating large customers to internalize testing operations to capture margin.
Competitive Landscape: Companies like Invitae ($NVTA) and others in the genomics space have faced their own significant challenges, indicating that the entire sector faces headwinds beyond Fulgent Genetics' specific situation.
The collapse also raises questions about how thoroughly sell-side analysts and institutional investors had assessed Fulgent Genetics' customer concentration risks and revenue stability before the announcement.
Investor Implications and Legal Developments
The Kirby McInerney LLP investigation carries significant implications for shareholders on multiple fronts. Institutional and retail investors who purchased FLGT securities face both immediate paper losses and potential recovery opportunities through litigation.
Shareholder Recovery Potential: Securities class action lawsuits can recover damages for affected shareholders if violations are proven. However, recovery depends on establishing that management made material misstatements or omissions, that investors relied on those statements, and that damages resulted from reliance.
Pending Legal Discovery: The investigation phase will likely involve discovery requests examining internal communications, board minutes, and customer relationship documentation. These materials could either substantiate or undermine allegations that management failed in its disclosure obligations.
Stock Price Implications: The 38.1% decline reflects the market's immediate assessment of the customer loss. Whether the stock stabilizes, falls further, or recovers depends on whether Fulgent Genetics can secure alternative revenue sources or demonstrate that the customer loss represents an isolated incident rather than a systemic business model problem.
Broader Market Message: The situation serves as a cautionary tale for investors to scrutinize customer concentration disclosures and customer retention trends at companies dependent on large contracts. Management's failure to adequately warn shareholders about concentrated customer risks could trigger heightened scrutiny of similar business models elsewhere in the sector.
Looking Forward
The investigation by Kirby McInerney LLP will likely take months or years to resolve, but the immediate market verdict has already rendered its judgment: Fulgent Genetics shareholders have lost approximately $9.43 per share in value, reflecting either material mismanagement, inadequate disclosure, or both. Whether this decline represents fair price discovery following poor management or the result of actionable securities law violations remains to be determined through the litigation process.
Investors holding FLGT securities should carefully consider participation in the investigation, as it may represent their only avenue for potential recovery. Simultaneously, the broader market lesson extends beyond Fulgent Genetics: companies operating in consolidating industries with concentrated customer bases face elevated disclosure obligations and heightened scrutiny regarding the sustainability of their revenue models. The February 27 collapse of Fulgent Genetics' stock price serves as a stark reminder that customer concentration risk, when inadequately disclosed, can destroy shareholder value with shocking speed.